Search

Many traditional villages have been degraded to a certain extent due to urbanization and out-of-control management. In addition, due to the lack of recognition and continuation of spatial texture in some village conservation and planning that, in turn, resulting in the gradual disappearance of their distinctive landscape feature. Studying the spatial form of traditional villages helps preserve the authenticity of traditional villages as cultural landscape and inherits traditional historical characteristics. Using Puping Village in Zhangzhou City, Fujian Province as an example, this paper obtains the integrated information data of the village through UAV oblique photography, classifies and extracts the spatial constitution of the traditional village using digital technology, quantitatively analyses it from macroscopic to microscopic, and summarizes the spatial morphology analysis method of the traditional village. The results demonstrate that digital technology can effectively and accurately complete data collection and can provide an objective basis for zoning conservation of traditional villages based on the distinction between new and historic buildings. In addition, digital information collection on the traditional villages landscape features will prepare for the establishment of a database and comparative analysis in the future. We further suggest that digital technology analysis needs to be combined with traditional methods to have a deeper understanding of the formation process of village spatial morphology. The results of the practice in Puping Village show that the use of digital technology can provide a scientific basis for the protection and planning of traditional villages, and that this method is adaptable, which can help to efficiently collect and analyze data on landscape characteristics of other similar villages in China, and support innovative methodologies and technologies for China's rural revitalization efforts. [ABSTRACT FROM AUTHOR]

1. A new oral liquid formulation combining guaifenesin, pseudoephedrine and hydrocodone is effective in improving the symptoms of common cold. The pharmacokinetic properties of the individual components were evaluated in a randomized, open-label, four-period study in 12 healthy Chinese volunteers following single and multiple doses. The data were compared with data for the individual ingredients in Antuss®. 2. In the single-dose period, exposure levels (AUC andCmax) for guaifenesin, pseudoephedrine and hydrocodone increased directly as the dose of the oral liquid formulation increased from 5 to 15 mL. Only minor amounts of guaifenesin and hydrocodone were excreted in urine (∼0.10% and 4.66%, respectively). Pseudoephedrine was mainly excreted unchanged, with 44.95% of the dose excreted in urine within 24 h. After multiple dosing, there was no obvious accumulation of any drug, as assessed by AUC. When consideringCmax, there was a trend toward accumulation of hydrocodone and pseudoephedrine. The pharmacokinetic profiles of guaifenesin and pseudoephedrine in the oral liquid formulation were similar to those in the branded preparation, Antuss®. 3. The newly developed oral liquid formulation combining guaifenesin, pseudoephedrine and hydrocodone was safe and well tolerated and might provide a reliable alternative to the branded formulation for patients with common colds. [ABSTRACT FROM AUTHOR]

1. Ingestion of grapefruit juice and food could be factors affecting the pharmacokinetics of pirfenidone, a promising drug for treatment of idiopathic pulmonary fibrosis. 2. A randomized, open-label, three-period crossover study was carried out in 12 healthy Chinese male volunteers who were randomized to one of the three treatments: pirfenidone tablets (0.4 g) were orally administered to fasted or fed subjects, or with grapefruit juice. The washout period was 7 d. 3. Significantly reduced maximum plasma concentration (Cmax, 5.0 5 ± 1.39 versus 10.9 0 ± 2.94 mg·L− 1), modestly affected area-under-the-plasma concentration–time curve (AUC) from time zero to 12 h post dosing (AUC0–12 h, 21.8 9 ± 6.47 versus 26.1 6 ± 7.32 mg·h·L− 1) and delayed time to reachCmax(Tmax) were observed in fed group compared with fasted group. Similar effects onCmax(5.8 2 ± 1.23 versus 10.9 0 ± 2.94 mg·L− 1) and AUC0–12 h(modest but not statistically significant, 24.4 4 ± 7.40 versus 26.1 6 ± 7.32 mg·h·L− 1) were observed for grapefruit juice compared to fasted subjects. 4. Co-administration of pirfenidone with grapefruit juice resulted in modestly reduced overall oral absorption and significantly reduced peak concentrations compared to fasting, which was similar to effect of food ingestion. No adverse events were observed in the study, but relatively dramatic reduction of peak concentrations should raise concerns for clinical efficacy and safety. [ABSTRACT FROM AUTHOR]

1. Pitavastatin is an effective treatment for primary hyperlipidemia and mixed dyslipidemia. The aim of the present study was to investigate the effect of food on the pharmacokinetic properties and bioequivalence of the original, branded, formulation of pitavastatin calcium and a new generic formulation in healthy Chinese male subjects under fasting and fed conditions. 2. Under fasting and fed conditions, 90% CIs of the geometric mean of generic/branded AUC0–48 hratios were 92.2–102.4%, 93.1–104.5%, the ratios of ln(AUC0–∞) were 92.6–103.7%, 93.2–103.5%, and ln(Cmax) ratios were 90.7–110.3%, 84.7–100.8%, respectively. The generic and branded formulations were bioequivalent in terms of rate and extent of absorption under both the conditions. The average values of AUC0–48 h, AUC0–∞andCmaxdecreased noticeably following a high-fat breakfast. Values for AUC0–48 hwere 87.69% and 83.7%, values for AUC0–∞were 87.5% and 84.6%, and values forCmaxwere 45.0% and 50.4% in subjects given the generic and branded preparations, respectively. The absorption of pitavastatin calcium tablets was delayed following a high-fat meal, withTmaxincreasing by up to 2.43-fold. 3. Both formulations were generally well tolerated, with no serious adverse reactions reported. The newly developed generic formulation may provide a reliable alternative to the branded tablets for patients with primary hyperlipidemia or mixed dyslipidemia. [ABSTRACT FROM AUTHOR]